INMUNEBIO
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
INMUNEBIO
Industry:
Biotechnology Commercial Industrial Medical
Founded:
2015-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.inmunebio.com
Total Employee:
11+
Status:
Active
Contact:
(858) 964 3720
Total Funding:
103.21 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Font Awesome Apache Mobile Non Scaleable Content
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
bkm Capital Partners
A fund manager specializing in the acquisition and improvement of value-add multi-tenant industrial properties across the Western U.S.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
EVO Group
EVO Group is specialist multi-channel distributor of business supplies and services.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
SeQure DX
SeQure DX is in the business activities at non-commercial site business.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Current Advisors List
Board_member
Board_member
2016-09-01
Board_member
2015-09-01
Board_member
2016-12-01
Board_member
2018-03-01
Current Employees Featured
David J. Moss CFO @ INmuneBIO
CFO
Raymond J. Tesi President , CEO & CMO @ INmuneBIO
President , CEO & CMO
2015-09-01
Mark Lowdell CSO, Founder & CMO @ INmuneBIO
CSO, Founder & CMO
2016-05-01
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - INmuneBIO
Toucan Capital
Toucan Capital investment in Post-IPO Equity - INmuneBIO
Alector
Alector investment in Post-IPO Equity - INmuneBIO
Official Site Inspections
http://www.inmunebio.com Semrush global rank: 4.62 M Semrush visits lastest month: 2.18 K
- Host name: 172.67.215.163
- IP address: 172.67.215.163
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "INmuneBIO"
INmune Bio Inc.
INmune Bio Inc. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. Our pipeline consists of first in class therapies …See details»
About Us - INmune Bio
J. Kelly Ganjei is the CEO and President of AmplifyBio, LLC, a contract research organization focused on helping advanced therapy clients navigate the concept to commercial journey. Mr. …See details»
Corporate Overview - INmune Bio
Taking the brakes off of the most powerful weapon in the fight against disease: our immune system. INmune Bio Inc. is a clinical stage biotechnology company that is developing new …See details»
INmuneBIO - Crunchbase Company Profile & Funding
Organization. INmuneBIO . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. INmune Bio is developing therapies that harness the patient’s immune system to treat …See details»
INmune Bio, Inc. (INMB) Company Profile & Facts - Yahoo Finance
See the company profile for INmune Bio, Inc. (INMB) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
INmune Bio Inc. - LinkedIn
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes …See details»
INmune Bio, Inc. (INMB) Company Profile & Overview - Stock …
225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 United StatesSee details»
INmune Bio - Overview, News & Similar companies | ZoomInfo.com
Mar 29, 2024 INmune Bio contact info: Phone number: (858) 964-3720 Website: www.inmunebio.com What does INmune Bio do? INmuneBio,Inc. is a publicly traded …See details»
INmune Bio Company Profile 2024: Stock Performance & Earnings
INmune Bio General Information Description. INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a …See details»
INmuneBIO - Funding, Financials, Valuation & Investors
INmuneBIO is registered under the ticker NASDAQ:INMB . Their stock opened with $8.00 in its Jan 15, 2019 IPO. INmuneBIO is funded by 3 investors. Silicon Valley Bank and Toucan …See details»
INmuneBIO - Contacts, Employees, Board Members, Advisors
Organization. INmuneBIO . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED …
Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing …See details»
INmune Bio - Craft
Oct 29, 2024 INmune Bio is a clinical-stage biotechnology company that develops immunotherapies that reprogram a patient’s innate immune system. It offers INKmune, an NK …See details»
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in
Sep 30, 2024 info@inmunebio.com Daniel Carlson Head of Investor Relations (415) 509-4590 dcarlson@inmunebio.com. Investor Contact: Mike Moyer Managing Director – LifeSci AdvisorsSee details»
subpage banner (Patients) - inmunebio.com
At INmuneBio, we view Alzheimer’s as an immunologic disease with the neurological symptoms of dementia. Approaching Alzheimer’s disease as an immunologic disease changes the drug …See details»
INmune Bio Announces $13.0 Million Registered Direct Offering
Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company …See details»
Pipeline - INmune Bio
A leading biotechnology company focused on modulating components of the innate immune system to activate a response against cancer and Alzheimers.See details»
subpage banner (Our science) - INmune Bio
INKmune is unique. INKmune works within the body to activate the patients own NK cells against multiple forms of cancer. Unlike other NK Cell treatments that require external manipulations …See details»
INmune Bio, Inc. (INMB) Stock Price, News, Quote & History
Find the latest INmune Bio, Inc. (INMB) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
2024 news - INmune Bio
Dec 10, 2024 INmune Bio Inc. Completes Repayment of Silicon Valley Bank DebtSee details»